Please use this identifier to cite or link to this item:
Title: Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications.
Authors: Morado, Marta
Freire Sandes, Alex
Colado, Enrique
Subirá, Dolores
Isusi, Paloma
Soledad Noya, María
Belén Vidriales, María
Sempere, Amparo
Ángel Díaz, José
Minguela, Alfredo
Álvarez, Beatriz
Serrano, Cristina
Caballero, Teresa
Rey, Mercedes
Pérez Corral, Ana
Cristina Fernández Jiménez, María
Magro, Elena
Lemes, Angelina
Benavente, Celina
Bañas, Helena
Merino, Juana
Castejon, Celine
Gutierrez, Olivier
Rabasa, Pilar
Vescosi Gonçalves, Matheus
Perez-Andres, Martin
Orfao, Alberto
PNH working group of the Iberian Society of Cytometry (SIC)
Keywords: flow cytometry;fluorescence cytometry;hematology;myelodysplastic syndrome;standardization
metadata.dc.subject.mesh: Anemia, Aplastic
Flow Cytometry
Hemoglobinuria, Paroxysmal
Myelodysplastic Syndromes
Prospective Studies
Retrospective Studies
Issue Date: 1-Oct-2016
Abstract: Although consensus guidelines have been proposed in 2010 for the diagnostic screening of paroxysmal nocturnal hemoglobinuria (PNH) by flow cytometry (FCM), so far no study has investigated the efficiency of such medical indications in multicentric vs. reference laboratory settings. Here we evaluate the efficiency of consensus medical indications for PNH testing in 3,938 peripheral blood samples submitted to FCM testing in 24 laboratories in Spain and one reference center in Brazil. Overall, diagnostic screening based on consensus medical indications was highly efficient (14% of PNH+ samples) both in the multicenter setting in Spain (10%) and the reference laboratory in Brazil (16%). The highest frequency of PNH+ cases was observed among patients screened because of bone marrow (BM) failure syndrome (33%), particularly among those with aplastic anemia (AA; 45%) and to a less extent also a myelodysplastic syndrome (MDS; 10%). Among the other individuals studied, the most efficient medical indications for PNH screening included: hemolytic anemia (19%), hemoglobinuria (48%) and unexplained cytopenias (9%). In contrast, only a minor fraction of the patients who had been submitted for PNH testing because of unexplained thrombosis in the absence of cytopenia, were positive (0.4%). In summary, our results demonstrate that the current medical indications for PNH screening by FCM are highly efficient, although improved screening algorithms are needed for patients presenting with thrombosis and normal blood cell counts. © 2016 International Clinical Cytometry Society.
metadata.dc.identifier.doi: 10.1002/cyto.b.21480
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.